News

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...
U.S. stock futures ticked up Friday morning, supported by a mostly upbeat earnings season even as several major names posted ...
Separately, Sareptea said last week that it would pause the development of most of its experimental gene therapies for a different type of muscular dystrophy. The stoppage came after one of the ...
The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...